Info

Paramount BioSciences is a global pharmaceutical development and healthcare investment firm that conceives, nurtures, and supports new biotechnology and life-sciences companies. The company has a keen eye for finding and developing novel therapeutic medicines that have, in our opinion, significant market potential. It assesses promising drug candidates from around the globe, from academic centers to biotechnology firms to pharmaceutical companies. Once compounds are in-licensed, selected members of the Paramount BioSciences Executive Team -- each member has significant life sciences industry experience, as described in their bios -- supported by approximately 80 in-house professionals, manages their entire development cycle, supporting all aspects of drug development including manufacturing, formulation, technology transfer, pharmacology, toxicology, clinical development, regulatory, quality assurance, commercialization, and life cycle management. After technologies are in-licensed and management teams are recruited to run portfolio companies built around novel therapeutics, Paramount BioSciences arranges for financing through its affiliate Paramount BioCapital, Inc., a FINRA registered broker-dealer. The affiliate's financial professionals have experience with securities and corporate transactions, including financings and mergers and acquisitions. Paramount BioSciences has a global reach with approximately 80 employees in five offices, including New York (global headquarters), San Diego (co-headquarters), London, Cambridge, MA., and Wilmington, N.C. For office locations, phone numbers, and directions please visit our contact page. Paramount BioSciences dedicates its own capital to seed portfolio companies through formation, the in-licensing of drug candidates and the initial stages of product development. Additional financing for the portfolio companies may be raised through Paramount BioCapital, Inc. an affiliated broker-dealer and FINRA member firm.